A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events

BACKGROUND: Patient perspectives are fundamental to defining tolerability of investigational anti-neoplastic therapies in clinical trials. Phase I trials present a unique challenge in designing tools for efficiently collecting patient-reported outcomes (PROs) given the difficulty of anticipating adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Janse van Rensburg, Helena J., Liu, Zhihui, Watson, Geoffrey A., Veitch, Zachary W., Shepshelovich, Daniel, Spreafico, Anna, Abdul Razak, Albiruni R., Bedard, Philippe L., Siu, Lillian L., Minasian, Lori, Hansen, Aaron R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421959/
https://www.ncbi.nlm.nih.gov/pubmed/37419999
http://dx.doi.org/10.1038/s41416-023-02307-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421959/
https://www.ncbi.nlm.nih.gov/pubmed/37419999
http://dx.doi.org/10.1038/s41416-023-02307-w

Ejemplares similares